Nkarta

CompanyUnited States

Nkarta develops one asset, in phase 1 (NKX101 in adult aml). Mostly cell therapy; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1
  • NKX101

    Engineered natural killer cells recognize NKG2D ligands on malignant cells and kill them.

    Phase 1, Cell therapy, adult aml, mds

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies2

Intelligence